The EPSC-based approaches to study the cellular and molecular mechanisms of PID and the drug development

Link genotype to cellular phenotype through genetically defined stem cell-based models of human immune disease by EPSC technologies, and use patient-derived EPSCs and isogenic EPSCs carrying engineered immune susceptibility mutations for the development of personalized stem cell-based phenotyping assays